DEVELOPMENT OF ANTISENSE DRUG TARGETING PCSK9

被引：0
|
作者：
Harada-Shiba, M. [1 ]
Wada, F. [1 ]
Tachibana, K. [2 ]
Yamamoto, T. [2 ]
Kobayashi, T. [2 ]
机构：
[1] Natl Cerebral & Cardiovasc Ctr Res Inst, Suita, Osaka, Japan
[2] Osaka Univ, Suita, Osaka, Japan
来源：
ATHEROSCLEROSIS | 2018年 / 275卷
关键词：
D O I：
10.1016/j.atherosclerosis.2018.06.897
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
W4:4
引用
收藏
页码：E4 / E5
页数：2
相关论文
共 50 条
  • [31] PCSK9 inhibitors
    Farnier, Michel
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) : 251 - 258
  • [32] The mystery of PCSK9
    Attie, AD
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (08) : 1337 - 1339
  • [33] PCSK9 IN YOUTH
    Baass, A.
    Dubuc, G.
    Lambert, M.
    Davignon, J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [34] Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
    Punch, Emily
    Klein, Justus
    Diaba-Nuhoho, Patrick
    Morawietz, Henning
    Garelnabi, Mahdi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (03):
  • [35] Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
    Corsini, Alberto
    Ginsberg, Henry N.
    Chapman, M. John
    PHARMACOLOGY & THERAPEUTICS, 2025, 268
  • [36] The PCSK9 decade
    Lambert, Gilles
    Sjouke, Barbara
    Choque, Benjamin
    Kastelein, John J. P.
    Hovingh, G. Kees
    JOURNAL OF LIPID RESEARCH, 2012, 53 (12) : 2515 - 2524
  • [37] The PCSK9 story
    Abifadel, Marianne
    Boileau, Catherine
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1341 - 1342
  • [38] PCSK9 inhibitors
    Gencer, Baris
    Lambert, Gilles
    Mach, Francois
    SWISS MEDICAL WEEKLY, 2015, 145
  • [39] PCSK9 pipeline
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (12) : 811 - 811
  • [40] PCSK9 pipeline
    Asher Mullard
    Nature Reviews Drug Discovery, 2016, 15 : 811 - 811
12345